Close Menu

NEW YORK (GenomeWeb) — Novacyt today reported revenues of €7 million ($8.1 million) for the first half of 2018, unchanged from the year-ago period as gains in the company's Lab21 protein diagnostics and Primerdesign molecular diagnostics units were offset by weak demand for its Novaprep cytology products.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.